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Abstract 
Current cancer therapies leave much to be desired because they are very harmful 
to the patient and cause a significant decrease in quality of life. Chimeric Antigen 
Receptors (CAR) are a promising novel approach for treating specific types of leukemia 
due to their binding affinity for proteins expressed solely on leukemia B cells. This 
approach increases specificity of how cells receive treatment, thus allowing for the 
destruction of cancerous cells while leaving the healthy cells unharmed. In this 
experiment, we show that production of CAR expressing exosomes (liposome like 
vesicles produced naturally by human cells) is possible through cell transfection. This 
finding demonstrates that a new wave of cancer therapeutics, that are more specific and 
have less harmful side effects, are producible.  
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Introduction 
Background 
Current cancer therapies are plagued by low success rates and a multitude of side 
effects that make the treatment agonizing for the patient. Targeted attack of cancer cells 
is thought to result in fewer side effects when compared to treatments that 
indiscriminately kill both healthy and cancerous cells.  New research has proven that the 
Chimeric Antigen Receptor (CAR) can effectively target and bind to leukemia B-cells. In 
our experiment we utilize exosomes, extracellular vesicles derived from the membrane of 
their host cells, to incorporate a CAR protein into the exosomal membrane.  The CAR-
expressing exosome can potentially be employed as a targeted drug-delivery vehicle to 
provide therapy for leukemia cells. We believe that CAR-expressing exosomes will be 
able to efficiently bind to specific cancer cells, thus allowing for more targeted therapy, 
and significantly reducing the side effects of other cancer treatments. 
Review of Field  
One of the main types of nanoparticles used in research is living nanoparticles.  
Living nanoparticles are naturally produced in the human body.  The most popular 
example is liposomes, which are spherical vesicles made from lipids that are used in cell-
cell communication. Currently, there are several FDA approved nanoparticle-assisted 
delivery agents for cancer therapy, and only one of which does not utilize liposomes as a 
delivery agent. The first nanoparticle delivery drug to be approved is Doxil, which 
received FDA approval in 1995, while the most recent is Vyxeos, which was approved in 
August of 20171. The only non-liposomal based nanoparticle delivery system is 
Abraxane, which is an albumin-bound paclitaxel nanoparticle. Although these drugs have 
been approved as cancer therapies, all of them use passive targeting, rather than the more 
effective active targeting. Passive targeting of tumors is mainly achieved through the 
                                               
1 Anselmo, Aaron C., and Samir Mitragotri. “Nanoparticles in the Clinic.” Bioengineering & 
Translational Medicine, vol. 1, no. 1, 2016, pp. 10–29., doi:10.1002/btm2.10003. 
2 
 
enhanced permeability and retention (EPR) effect, which means the drug tends to 
accumulate in areas of low vascularization, such as tumors. Active targeting is based on 
the technology to attach specific ligands to the surface of a drug delivery nanoparticle, 
which will then attach and bind to specific cancer cells2.  
 Another category of nanoparticles being explored for targeted therapies are non-
living nanoparticles, which are not naturally produced in the human body. The two most 
promising nanoparticles in this category are gold and titanium dioxide. Gold 
nanoparticles are being researched as drug delivery systems as well as other potential 
applications, like photothermal agents, contrast agents, and radiosensitisers3. Titanium 
dioxide nanoparticles are also being explored as drug delivery agents, and are being 
researched in vivo as well as in vitro4.  
 
Critique of Current Technology 
Although liposomes are naturally occurring, they do not naturally express 
membrane proteins. Thus, attaching antibodies to the surface of these nanoparticles is 
inherently more difficult. The increased difficulty of attaching ligands to the surface of 
these nanoparticles is the main reason why none of the FDA approved liposome drug 
delivery systems use active targeting, even though active targeting has been shown to be 
more effective for cancer treatment in preclinical studies5. Although there have been 
studies looking at targeted therapy using liposomes expressing monoclonal antibodies on 
their surface, all of these potential therapies have failed, in both efficacy as well as 
toxicity (mostly immunogenicity)6. Additionally, liposomes are one of the larger 
nanoparticles, which leads to difficulty passing blood barriers like the blood-brain barrier. 
While some limited advances have been made in crossing the blood brain barrier using 
                                               
2 Torchilin, Vladimir P. “Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example.” Drug Delivery Handbook of 
Experimental Pharmacology, 2009, pp. 3–53., doi:10.1007/978-3-642-00477-3_1. 
3 Jain, S, et al. “Gold Nanoparticles as Novel Agents for Cancer Therapy.” The British Journal of Radiology, vol. 85, no. 1010, 2012, 
pp. 101–113., doi:10.1259/bjr/59448833. 
4 Bogdan, Janusz, et al. “Nanoparticles of Titanium and Zinc Oxides as Novel Agents in Tumor Treatment: a Review.” Nanoscale 
Research Letters, vol. 12, no. 1, 2017, doi:10.1186/s11671-017-2007-y. 
5 Anselmo, Aaron C., and Samir Mitragotri. “Nanoparticles in the Clinic.” Bioengineering & Translational Medicine, vol. 1, no. 1, 
2016, pp. 10–29., doi:10.1002/btm2.10003. 
6 Sercombe, Lisa, et al. “Advances and Challenges of Liposome Assisted Drug Delivery.”Frontiers in Pharmacology, vol. 6, Jan. 
2015, doi:10.3389/fphar.2015.00286. 
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membrane-bound proteins on liposomes, these have also failed due to the poor 
pharmacokinetics and immunogenicity mentioned above7.  
Gold and titanium dioxide nanoparticles are not naturally occuring in the body, 
which means there are higher risks of toxicity. Both of these nanoparticles have been 
shown to be toxic to humans in potential therapeutic doses during in vivo studies8,9. 
Neither of these particles have the ability to express antibodies or other membrane 
proteins, which means that they must rely on passive targeting through EPR or other 
mechanisms, instead of the more effective active targeting. Additionally, there are 
environmental concerns with both of these nanoparticles. Since they do not degrade, they 
tend to accumulate in tissues, which causes toxicity in humans as well as 
bioaccumulation in the natural world during their manufacturing10. All of these risks and 
challenges to using non-living nanoparticles are a major roadblock to their acceptance as 
a drug-delivery agent by the FDA.  
Project Goal 
Our aim is to avoid the problems of other nanoparticles by using naturally 
secreted exosomes as vehicles for targeted delivery. In order to target leukemia cells, we 
will integrate the Chimeric Antigen Receptor (CAR) into the exosome membrane. CAR 
is composed of three different proteins as depicted in Figure 1. scFV is a single chain 
antibody that has a high binding affinity for leukemia cells and drives the exosomes 
towards the cancerous cell. tVSVG is a truncated membrane protein which allows for the 
components of CAR to attach to both the inside and outside of the exosome. This protein 
ensures that the CAR protein will be expressed on the exosome membrane and nowhere 
else. Green Fluorescent Protein (GFP) serves as a marker to allow us to differentiate 
between exosomes expressing the CAR protein and exosomes without the CAR protein. 
In order to engineer cells that produce exosomes with the CAR protein, we must integrate 
                                               
7 Vieira, Débora B, and Lionel Gamarra. “Getting into the Brain: Liposome-Based Strategies for Effective Drug Delivery across the 
Blood&Ndash;Brain Barrier.”International Journal of Nanomedicine, Volume 11, 2016, pp. 5381–5414., doi:10.2147/ijn.s117210. 
8 Shi, Hongbo, et al. “Titanium Dioxide Nanoparticles: a Review of Current Toxicological Data.” Particle and Fibre Toxicology, vol. 
10, no. 1, 2013, p. 15., doi:10.1186/1743-8977-10-15. 
9 Lopez-Chaves, Carlos, et al. “Gold Nanoparticles: Distribution, Bioaccumulation and Toxicity. In Vitro and in Vivo Studies.” 
Nanomedicine: Nanotechnology, Biology and Medicine, 2017, doi:10.1016/j.nano.2017.08.011. 
10 Shah, Syed Niaz Ali, et al. “Hazardous Effects of Titanium Dioxide Nanoparticles in Ecosystem.” Bioinorganic Chemistry and 
Applications, vol. 2017, 2017, pp. 1–12., doi:10.1155/2017/4101735. 
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the CAR DNA into the cell’s genome using transfection. Transfection is the process of 
deliberately introducing genetic material into the cells and allowing the cells to naturally 
uptake the DNA.  If successful, we plan to observe engineered exosomes that express the 
CAR protein and can effectively bind to leukemia B-cells. 
Backup Plan 
Our backup plan was to purchase professionally prepared lentiviruses that have 
the desired DNA inside of them. We could then integrate the CAR DNA into the genome 
of the cell using lentiviral transduction.  This plan is very likely to work because it does 
not involve much experimentation on our part.  We would simply be adding the 
lentiviruses into the dish with cells and determining if the desired gene had been 
expressed. The main reason that this option is our backup is because it is very expensive11 
and we are already using nearly all of our allocated money on our first experimental 
design, so we would not be able to afford this without applying for extra financial 
support. 
Significance 
 We believe that our technology will have a large impact on the future of cancer 
therapies. We currently have two ideas about how this technology will be built upon in 
the future. The first possibility is that the same model that we are using will be adapted to 
contain a toxic protein rather than GFP so that when the exosomes bind to leukemia cells 
they will deposit that protein, leading to the death of the cell. The second possibility is 
that the single chain antibody could be changed to target other types of disease states. 
That means that this technology could potentially be adapted for treatment of a wide 
range of diseases. 
Team and Project Management 
Table 1: Team Members and Faculty Advisor 
                                               
11 Inc., Applied Biological Materials. “Custom Lentivirus.” Custom Lentivirus, www.abmgood.com/Custom-Lentivirus-
Subcloning-Services.html. 
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Team Members 
Michael Pierotti* Biomolecular Engineering mpierotti@scu.edu  
Matthew Piro Pre-Med Bioengineering mpiro@scu.edu  
Pete Mitchell Biomolecular Engineering psmitchell@scu.edu  
Faculty Advisor 
Bill Lu (MD, PhD) School of Bioengineering blu2@scu.edu  
 
* Denotes primary contact 
Management Approach 
An excerpt from our team charter effectively displays our management style throughout 
our project: 
 “We will all be responsible for a portion of each milestone or objective, and the 
portion that each individual will be responsible for every week will be assigned by the 
weekly team leader, a role that switches from student to student each week. Our main 
expectations are that everyone will be professional in communications, all work will be 
completed on time, and all work will be held to our usual standard and the standard of Dr. 
Lu.” 
Budget and Issues 
Our full project budget can be viewed in Appendix D. Our experiment is currently 
operating within our budget constraints. However, since we only have $110 in reserve, 
we do not have much room for error. The only upcoming part of the experiment which 
might force us to use this reserve budget would be sending a sample of our exosomes out 
to a company in order for them to test the concentration. Since we are unsure whether we 
will end up doing this supplement to our testing protocol, we may not use the last of our 
budget reserves.   
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Timeline and Issues 
Table 2: Timeline 
 Fall Quarter Winter Quarter Spring Quarter 
Weeks 1-3 Safety training, 
create outline for 
the year 
Run experiments Finish experiments 
(if necessary), 
create + finish 
powerpoint 
Weeks 4-7 Cell culture 
technique practice, 
budget proposal, 
finalize experiment 
procedure 
 
Run experiments 
 
Create draft of 
presentation script, 
continue writing 
report 
Weeks 8-10 Kill cells before 
break, write 
introduction section 
of paper 
Run experiments, 
compile data 
Finish presentation 
script + written 
report, practice 
presentation, final 
presentation and 
report 
Note: Gantt charts with further information can be seen in Appendix B.  
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Chapters of Project 
The goals we have for this project are stratified in order of importance, due to the 
unpredictable nature of working with living cells. Our baseline goal was to successfully 
transfect the HEK 293 cells with the genes coding for the CAR protein. We could verify 
this through simple fluorescent microscopy.  If our cells are glowing green, we know that 
the GFP gene is being transcribed. We could further verify successful incorporation into 
the cells genome by introducing the cells into media with added puromycin. Since the 
gene we added encoded for puromycin resistance, only the cells that had incorporated the 
gene into their genome would survive. This was our baseline goal to prove that we could 
successfully transfect cells so they could generate exosomes with the CAR protein. 
Details of Key Constraints 
 We have two main constraints for our project. The first is to ensure the 
transfection of our DNA is successful. We can validate this through viewing of the cells 
through a fluorescent microscope to check for GFP, as well as introducing the cells to 
media with added puromycin to check if they express the puromycin resistance gene 
introduced through the CAR DNA. The next key constraint is to ensure that the cells 
actually produce exosomes. Although background research states that they will, we will 
conduct an exosome harvest to validate this. We will also obtain the concentration to 
know the production rate for our exosomes to prove that the transfection does not 
interfere with this efficiency.  
Detailed Design Description 
 The exosome that we are engineering is depicted in Figure 1 of the appendix. The 
main features of this nanoparticle are the CAR-T single chain antibody, the truncated 
VSVG membrane protein, and the green fluorescent protein (GFP) housed within the 
body of the exosome. The CAR-T single chain antibody is the protein that has a high 
binding affinity for a receptor on Leukemia B cells. The truncated VSVG membrane 
protein ensures that this complex will be localized to exosomes because it is only present 
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in the membranes of exosomes. The GFP that is housed within the exosome functions as 
a tag so that we can easily see if the cells are expressing this protein complex by 
detecting the green fluorescence using fluorescence microscopy.  
 To create our desired exosome we are going to transfect HEK 293 cells with the 
DNA vector shown in Figure 2. This vector codes for the protein complex to be created 
and has a few other functionalities as well. It includes a promoter (MSCV) to drive the 
production of our protein, a secondary promoter (EF1) that will increase the cells 
puromycin resistance expression (Puro) along with a poly A tail for stability.  
Detailed Supporting Analyses 
We will examine the concentrations of nanoparticles (exosomes) produced, as 
well as testing their ability to be uptaken by control cells.  
Expected Results 
 The results are mainly focused on determining if exosomes that have a binding 
affinity for leukemia B cells can be produced. The binding affinity of CAR-T has already 
been proven12, so the experiment will be focused on production levels of exosomes. The 
data will be comparing the concentration of nanoparticles/ml to other concentrations of 
exosomes and liposomes produced for therapeutic purposes. We also expect that there 
will be uptake of the exosomes into the control cells. 
 
  
                                               
12 Arcangeli, Silvia et al. “Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for 
the Targeting of Acute Myeloid Leukemia” Molecular Therapy , Volume 25 , Issue 8 , 1933 - 1945 
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Materials and Methods 
Passaging HEK 293 Cells 
Check cells under the microscope.  They should be passaged at 70-80% 
confluency. Warm cell media (DMEM), PBS, and trypsin in a 37°C water bath. Then 
move the cells, DMEM, PBS, trypsin, aspirating tips, pipet tips, pipetman, and P1000 
micropipette to the hood. Aspirate the old media out of the well plate. Add 3 ml of PBS 
to the plate, aspirate out the PBS, and add 1.5 ml of Trypsin dropwise throughout the 
plate. Put the plate in the incubator for 2 minutes. Add 5 ml of DMEM to the plate. Pipet 
contents of the plate into a microcentrifuge tube. Centrifuge the tube with for 5 minutes at 
1500 rpm. Label the new plate with initials, cell type, passage number, and date. Aspirate 
out the liquid in the tube.  Do not aspirate out the cell pellet. Add 7 ml of DMEM to the 
new 60mm plate, resuspend cell pellet in 4 ml of DMEM,  and micropipet 250 μl from 
the centrifuge tube to the new plate. 
Transfection of HEK Cells 
First, add 300 μl of OptiMem to 2 Microcentrifuge tubes and label them “DNA” 
and “Transfection Reagent”. Next add 6ug of desired DNA to the tube labeled DNA. 
Then add 30 μl of PEI to the tube labeled “Transfection Reagent” and let rest for 10 
minutes. Transfer all contents of the “DNA” tube into the “Transfection Reagent” tube 
and gently mix, wait 20 minutes. Finally, plate 200 μl into each well and swirl gently. For 
control solution, repeat same steps as listed above without adding the DNA. 
Passaging HEK 293 Cells (From 6-well Plate onto 60 mm Plate) 
Check cells under the microscope.  Cells should be passaged at 70-80% 
confluency. Warm cell media (DMEM), PBS, and trypsin in a 37°C water bath. Move 
cells, DMEM, PBS, trypsin, aspirating tips, pipet tips, pipetman, and P1000 micropipette 
to the hood. Aspirate the old media out of the well plate, add 1.5 ml of PBS to the plate, 
aspirate out the PBS, and add 1 ml of Trypsin dropwise throughout the plate. Then put 
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the plate in the incubator for 2 minutes. Next, add 3 ml of DMEM to the plate, then pipet 
contents of the plate into a microcentrifuge tube. Centrifuge the tube with for 5 minutes at 
1500 rpm. Label the new 60 mm plate with initials, cell type, passage number, and date. 
Aspirate out the liquid in the tube.  Do not aspirate out the cell pellet. Add 3 ml of 
DMEM to the new plate, resuspend cell pellet in 2 ml of DMEM, and micropipet 250 μl 
from the centrifuge to the new normal-sized plate. 
Passaging onto 100 mm Plates for Exosome Harvest 
Check cells under the microscope.  They should be passaged at 70-80% 
confluency. Warm cell media (DMEM), PBS, and trypsin in a 37°C water bath. Then 
move the cells, DMEM, PBS, trypsin, aspirating tips, pipet tips, pipetman, and P1000 
micropipette to the hood. Aspirate the old media out of the well plate. Add 3 ml of PBS 
to the plate, aspirate out the PBS, and add 1.5 ml of Trypsin dropwise throughout the 
plate. Put the plate in the incubator for 2 minutes. Add 5 ml of DMEM to the plate. Pipet 
contents of the plate into a microcentrifuge tube. Centrifuge the tube with for 5 minutes at 
1500 rpm. Label the new plate with initials, cell type, passage number, and date. Aspirate 
out the liquid in the tube.  Do not aspirate out the cell pellet. Add 20 ml of DMEM to the 
new 100 mm plate, resuspend cell pellet in 4 ml of DMEM,  and micropipet 1.5 ml  from 
the centrifuge tube to the new plate. 
Exosome Harvest for Exosomes in Suspension on 100 mm Plates 
After cells have been plated on 100 mm plates for one day, aspirate off the 
DMEM and add 20 ml of Ultraculture. Place back in incubator and leave for 2 days. After 
2 days have passed remove media using a pipette and place in a 50 ml centrifuge tube. 
Centrifuge at 1500 x g for 10 minutes and then filter through a 0.2um filter. Divide the 
current volume by 4 and add that much EXO-TC to the tube. Leave in the 4°C  fridge 
overnight. The next day centrifuge the exosome suspension at 3000 x g for 90 minutes. 
Remove the supernatant and let the tube dry, the exosomes will be in a pellet at the 
bottom. Resuspend the exosomes in 100 μl of PBS and place into a microcentrifuge tube.  
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Plating for Confocal Microscopy 
 During routine passaging of cells, once cells are resuspended in new media, plate 
100 μl of the cell suspension onto a glass bottom plate with 1.9 ml DMEM. Wait two 
days for cells to attach to plate, then aspirate off DMEM, and add 2 ml of PBS.  
DAPI Staining Procedure 
 Create DAPI solution of 300 nM by diluting as needed with PBS. Take control 
cells on glass bottom plate and wash 3 times with PBS. Aspirate off PBS and add enough 
DAPI solution to cover the cells. Incubate for 5 minutes, then aspirate off DAPI solution. 
Wash 3 times with PBS, and then take confocal microscopy pictures as necessary.  
Exosome Uptake Experiment into Control HEK 293 Cells 
After isolating exosomes, take exosomes and resuspend in 100 μl of PBS. Add 
exosome suspension into glass bottom plate with control HEK cells. Take confocal 
microscopy pictures as necessary.    
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Results 
 
Figure 1: Experimental Cells 31 Days after Transfection. Figure 1 shows our experimental cells 31 days 
after transfection. Figure 1A,D show the experimental cell lines in phase lighting. 1B,E show the cells 
being exposed to green fluorescent light. 1C,F show the phase and green fluorescent light images 
overlapped for both of the conditions. As you can see there is GFP being expressed in both of the 
experimental conditions.  
A CB
FED
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Figure 2: Cells 79 Days after Transfection: Figure 2 shows both experimental lines of cells and a control 
line of cells 79 days after transfection. 2A,G,D show all of the conditions in phase lighting. 2B,E,H show 
each condition under green fluorescent light. Finally, 2C,F,I show an overlay of the phase and green 
fluorescent light in each condition. 
 
 
Figure 3: DAPI Staining of Experimental Cells Figure 3 shows two lines of experimental cells and a 
control line of cells exposed to green fluorescent and blue fluorescent light after they have been stained by 
DAPI, a compound that stains the nucleus of cells. 3A shows the control line while 3B,C show the 
experimental cell lines. 
 
A B C
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Figure 4: Exosome Harvest Efficiencies. Figure 4 is a graph of our average yields for exosome harvests, 
done in triplicate. There is no significant difference in the control and experimental yields (p > 0.05). 
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Figure 5: Exosome Uptake Experiment. Figure 5 displays our exosome uptake experiment. In this 
experiment we exposed regular HEK 293 cells to 100μl of exosomes to ensure that they could still be 
uptaken. We monitored the cells for 48 hours after initial exposure. 5A,C show the cells in phase lighting 
while 5B,E show them under green fluorescent lighting at 24 and 48 hours respectively. 5C,F show an 
overlay at each of those timepoints. In 5F you can see that 48 hours after exposure there was a fair amount 
of uptake into the cells.  
16 
 
Discussion 
In Figure 1, the confocal microscopy pictures taken 31 days after transfection 
confirms the initial success of the transfection protocol. There is a strong GFP signal in 
the pictures, and the overlays in Figures 1C and 1F show that the fluorescence is coming 
from the cells themselves.  
Although the confocal microscopy pictures in Figure 1 confirmed the initial 
success of the transfection, they did not confirm the successful integration of the 
engineered vector into the genome of the cells themselves, which would indicate a stable 
cell line. In Figure 2, which depicts more confocal microscopy pictures taken 79 days 
after transfection, the cells are still stably producing GFP, which confirms the integration 
of the vector into the genome and validates our stable cell lines.  
After validating the stable cell lines, the next step was to ensure the GFP signal 
was coming from the engineered exosomes and was not being generated in any other part 
of the cell. This verification was done through the use of DAPI staining, which is a blue 
fluorescent stain that binds to DNA and stains the nucleus. Since exosomes are produced 
in the cytosol of the cell, the expectation is that the GFP signal is coming from only the 
cytosol and not the nucleus. Comparing the GFP and the DAPI fluorescence could reveal 
precisely where the individual signals were coming from. This is shown in Figure 3B and 
3C, where the two engineered cell lines have green and blue fluorescence that is not 
overlapping. This lack of overlap shows that the exosomes are responsible for the GFP 
signal and also that they have not entered the nucleus, which is not seen in control 
exosomes.  
Figure 4 contains the average harvest yields for the engineered and the control 
exosomes. Each condition had three harvests, with the average + the SEM shown. There 
is no significant difference between the harvest yields of the two conditions. This 
validates one of the main goals of the project, which was to be able to produce 
engineered exosomes with the same cells for an indefinite period of time.  The similar 
yields from engineered and control cell lines means that the vector we engineered into the 
exosomes did not significantly affect their production.  
Lastly, the ability of engineered exosomes to be taken up by cells needed to be 
17 
 
verified. This was done by isolating and purifying the engineered exosomes, and then 
reintroducing them into a plate with control HEK cells. If the control cells could take up 
the engineered exosomes, then this proves that the engineered antigen did not make the 
exosomes too big to cross cell barriers, which would be an integral part of any future 
exosome treatment. In Figures 5A, B, and C, the exosomes are in solution but not being 
taken up by the cells 24 hours after reintroduction to control cells. However, at 48 hours 
after reintroduction, in Figure 5F, exosomes expressing GFP are inside the cytosol of the 
control cells. This proves that not only are the exosomes still expressing the vector in 
their genome, but also that the antigen did not affect their uptake into control cells.  
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Summary and Conclusion 
Project Objectives 
 Overall, our project focuses on addressing a widespread disease called leukemia, 
a type of blood cancer which impacts thousands of people each year.  Although several 
current treatments exist, they lack specificity and targeting capabilities, thus resulting in a 
wide range of debilitating side effects.  In order to combat these challenges, our project 
deals with naturally occurring living nanoparticles called exosomes.  The membrane 
proteins found on the surface of exosomes allow for exosomes to be engineered to have a 
high binding affinity for leukemia cells.  Researchers have developed the Chimeric 
Antigen Receptor (CAR), which has been proven to bind to proteins found on the surface 
leukemia cells.  Our goal is to prove that a vector of CAR DNA can be integrated into the 
cell’s genome to produce CAR expressing exosomes without disrupting the cell’s normal 
production level of the exosomes.  These engineered exosomes can be used to deliver 
therapeutic drugs specifically to leukemia cells. 
 
Project Design Process 
Much of our project design process focused on figuring out what types of assays 
we wanted to utilize. Prior to senior year, we determined the DNA vector that we were 
going to use and decided upon integrating the DNA via transfection; however, we were 
unsure of how to quantify our data to prove our experiment was successful.  The main 
way we decided to accomplish this was through monitoring GFP expression via confocal 
microscopy.  Because GFP is one of the components of our CAR vector, it can be used to 
show that the transfection was successful and that our cell line now produces exosomes 
that express the CAR protein.  Furthermore, we needed to verify the GFP signal 
originated from the engineered exosomes and nowhere else in the cell.  We decided to 
employ DAPI staining, a blue fluorescent stain that binds to DNA and stains the nucleus, 
to identify the nucleus of the cells.  Ideally, there should be no overlap between the GFP 
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and the blue-stained nucleus because exosomes are produced in the cytosol.  Moreover, 
we wanted to prove that the transfection or presence of CAR did not interfere with the 
cell’s normal exosomes yield.  We chose to validate this by harvesting exosomes from 
both the control and experimental cell lines and comparing the values.  Finally, we 
wanted to demonstrate that the engineered exosomes could be reuptaken when introduced 
back into a cell line.  This is a crucial part for confirming that our innovation has 
potential as a drug delivery method in the future. 
 
Accomplishments 
 Overall, our results were as expected and our experiment was a success.  We were 
able to transfect the cells with CAR DNA.  We established a stable cell line by passaging 
and changing the cell media biweekly for over 3 months after transfection. This is a 
noteworthy milestone because a single mishap or contamination would nullify our 
research and force us to start over.  The expression of GFP via confocal microscopy after 
this time verifies that the DNA had successfully been integrated into the genome of the 
cells.  In addition, the DAPI staining procedure proved that exosomes were present in the 
cytosol of the cell as one would expect.  Next, we found no significant difference 
between the exosome harvest efficiencies in the control and experimental control lines.  
This shows that the introduction of CAR does not inhibit the cell’s ability to generate 
exosomes.  Lastly, we verified that the engineered exosomes could be reuptaken back 
into a cell line, which is essential in proving that exosomes could serve as a viable drug 
delivery option.  In conclusion, our design worked and our project was successful.  We 
believe that the CAR expressing exosomes could feasibly be explored as an option to 
effectively treat leukemia in the future. 
Future Work 
In the future, one could send out the engineered exosomes to a third party 
company for analysis. This analysis would elucidate features of the exosomes that were 
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beyond the capacity available at Santa Clara University such as the size of the exosomes 
and more accurate harvest values.  
 The next step would be to conduct an experiment in which the affinity of the 
engineered antigen itself could be measured. To accomplish this, one would need cells 
expressing the specific biomarker on leukemia cells.  One could ten put both the 
leukemia biomarker cells as well as control HEK cells onto the same plate and introduce 
the engineered exosomes into the plate, similar to the experiment conducted in Figure 5. 
After, one could use confocal microscopy to visualize whether or not the engineered 
exosomes were preferentially uptaken by the leukemia cells over the control cells. This 
would give valuable insight into how the engineered exosomes would act in the human 
body, where there are many different cell types in the same area.  
 The two stable cell lines that we engineered were cryopreserved for potential 
future work. If another group of students were to continue this project, they would have a 
significant time advantage to perform verification experiments, a stable cell line 
expressing the vector has already been established.  
 
Lessons Learned 
During the course of this year-long project, there were many aspect where our 
group thrived, and other shortcomings that we could have improved upon. There were 
things we could have done both before beginning the project and during the project itself 
that could have set us up for greater success. These follow, in no particular order. 
One way we could have improved was better planning prior to the senior design 
process. As a group, we were somewhat unprepared and did not have a clear picture of 
what our senior design project would be about until the end of junior year. This did not 
allow us to take specific courses that could have expedited our learning, which meant that 
we had to spend valuable project time learning the skills that could have been learned 
earlier. Specifically, our project involved a great deal of cell culture techniques. If we all 
had taken the cell culture lecture and laboratory prior to starting our project, we could 
have eliminated much of the learning curve in the initial stages of the project. This meant 
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that the back end of the project was cramped on time and we could not perform as many 
verification experiments as we would have liked.  
 
Engineering Standards and Realistic Constraints 
 
Various engineering standards and realistic constraints impact our project and 
should be considered.  First, our design leads to some economical constraints.  Producing 
CAR-expressing exosomes is a costly task that requires the use of high-quality, 
specialized equipment.  For example, simply maintaining the exosome producing cells 
requires the use of microscopes, incubators, aspirators, centrifuges, pipetman, and 
micropipettes in addition to the necessary cell media.  Therefore, the cost of production is 
quite high, which will likely drive up the price for the consumer and can lead to some 
ethical dilemmas.   
If the cost is high, patients of lower socioeconomic status may not be able to 
afford the treatment they need to fight Leukemia, while members of the upper class can 
afford the treatment.  This results in money potentially serving as the deciding factor for 
who lives or dies, which is undoubtedly an ethical concern.  In addition to monetary 
ethical issues, our project uses HEK 293 cells (STEM cells) as the basis for our 
experiments, which are somewhat controversial.  HEK 293 cells are derived from human 
embryonic kidneys cells and are grown in tissue culture.  The use of human embryonic 
stem cells is controversial because human embryos are destroyed to harvest the cells and 
the question of when life begins is highly debated.   
Furthermore, manufacturing serves as another constraint because producing CAR-
expressing exosomes is a tedious tasks that requires a great deal of time and effort.  
Harvesting exosomes is a long process that is quite laborious.  Also, cell lines must be 
constantly maintained and sustained through passaging and changing media.  
Manufacturing time and exertion is a significant constraint that must be considered in our 
project. 
Moreover, sustainability is another engineering standard that should be addressed.  
After the CAR-expressing exosomes are harvested from the engineered HEK 293 cell, 
they are not very sustainable and will not last long on their own.  The exosomes must be 
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either used quickly for treatment or frozen down.  Even though the exosomes themselves 
are not sustainable, the cells which produce the exosomes are sustainable and can be 
maintained.  This help increase the sustainability of our project. 
Lastly, our experiment does raise some environmental issues.  Due to sterile 
technique, each pipet and aspirating tip can only be used once before being discarded.  
This results in the accumulation of an abundance of plastic waste from experiments.  For 
example, each passage uses 3 aspirating tips, 4 pipets, a well plate, a centrifuge tube, as 
well as a pair of gloves for each person working.  Although this may seem wasteful, it is 
a sacrifice we must make in order to prevent cell contamination. 
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Appendix A: Design  
 
 
Figure 6.  Design of CAR-Expressing Exosome 
 
 
Figure 7. Expression Vector 
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Appendix B: Gantt Charts 
 
Table 3: Gantt Charts 
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Appendix C: Final Presentation Slides 
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Appendix D: Budget 
Table 4: Detailed Budget  
Materials Budget (Complete Funding by Undergraduate Programs): 
● 293T packaging cells (ATCC # CRL-11268)    Supplied 
● Prepared plasmid DNA for:      $600.00 
○ CAR-t scFV 
○ tVSVG 
○ GFP 
● PEI:         $390.00 
● DMEM media (ATCC #30-2002):     Supplied 
● OptiMem Reduced Serum Media (Invitrogen # 31985-070): Supplied 
● FBS (ATCC #30-2020):      Supplied 
● Pen/Strep (ATCC #30-2300):      Supplied 
● 15mL Centrifuge Tubes (Fisher # 05-538-53F):   Supplied 
● 50mL Centrifuge Tubes (Fisher # 07-203-510):   Supplied 
● Qiagen Miniprep Kit:       $400.00 
○ Total:        $1,390.00 
○ Funding Received       $1,500.00 
○ Remaining Budget      $110.00 
 
